A Phase 2 interventional study of alirocumab SAR236553 (REGN727) and statins in Hypercholesterolaemia, sponsored by Sanofi. Completed at 16 sites in 10 countries. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-09-06.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 32nd largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 2, and was the 32nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 30th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 2, and was the 32nd registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 8 weeks of treatment in heterozygous familial hypercholesterolemia (heFH) participants aged of 8 to 17 years, with LDL-C >=130 milligrams per deciliter (mg/dL) (3.37 millimoles per litre [mmol/L]) on optimal stable daily dose of statin therapy +/- other lipid modifying therapies (LMTs) or a stable dose of non-statin LMTs in case of intolerance to statins for at least 4 weeks prior to the screening period.
Secondary Objective:
For Cohorts 1 to 3, a study duration of approximately 16-23 weeks (screening period: up to 6 (+1) weeks, open-label dose finding treatment period: 8 weeks, follow up period: 6-8 weeks).
For Cohort 4, a study duration of approximately 14-19 weeks (screening period up to 6 [+1] weeks, open-label dose finding treatment period: 12 weeks).
Optional extension period: up to a maximum of 2 years for the first participants enrolled in Cohorts 1 to 3, but a maximum of approximately 5 months for the first participants enrolled in Cohort 4.
For all participants who declined participation in the phase 3 study, their last alirocumab injection was on December 2018.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants with body weight less than (\<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT). Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still \< 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Period 1: Participants with body weight greater than or equal to (\>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT. Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still \< 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT. Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still \< 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT. Period 2: Participants with body weight \< 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT. Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48.
Drug: alirocumab SAR236553 (REGN727) · Drug: statins · Drug: ezetimibe · Drug: cholestyramine · Drug: fenofibrate · Drug: omega-3 fatty acids · Drug: nicotinic acid
Pharmaceutical form: solution Route of administration: subcutaneous injection
Also known as: Praluent
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
Percent change in calculated LDL-C was defined as 100\*(calculated LDL-C value at Week 8 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline. All available baseline and post-baseline calculated LDL-C value during the OLDFI efficacy treatment period \& within one of the analysis windows up to Week 8 were used in the model. OLDFI efficacy treatment period was defined as the period from first investigational medicinal product (IMP) injection to last OLDFI IMP injection + 21 days(for Cohorts 1 \& 2) or +35 days (for Cohorts 3 \& 4). Adjusted Least-squares (LS) mean \& standard error (SE) at Week 8 were obtained from mixed-effect model with repeated measures (MMRM) analysis, with fixed categorical effects of alirocumab dose/dose regimen (30 mg Q2W \[\<50 kg\], 40 mg Q2W \[\<50 kg\], 50 mg Q2W \[\>=50 kg\], 75 mg Q2W \[\>=50 kg\], 75 mg Q4W \[\<50 kg\],150 mg Q4W \[\>=50 kg\], 150 mg Q4W \[\<50 kg\] and 300 mg Q4W (\[\>=50 kg\] dose), time point \& dose/dose regimen-by-time point interaction.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
Absolute change in LDL-C was calculated by subtracting baseline value from Week 8 value. Adjusted LS means and SE were obtained using MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.
Time frame: Baseline, Week 8
Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8
Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
Time frame: At Week 8
Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8
Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
Time frame: At Week 8
Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4
Adjusted LS means and standard error at Week 12 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.
Time frame: Baseline, Week 12
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline value and post-baseline values in at least one of the analysis windows used in the model.
Time frame: Baseline, Week 8
Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baselines value and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Percent Change From Baseline in Lipoprotein(a) at Week 8
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively (with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
Time frame: Baseline, Week 8
Percent Change From Baseline in Fasting Triglyceride at Week 8
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
Time frame: Baseline, Week 8
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Percent Change From Baseline in Apolipoprotein A-1 at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Apolipoprotein B at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Lipoprotein(a) at Week 8
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
Time frame: Baseline, Week 8
Absolute Change From Baseline in HDL-C at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Fasting Triglyceride at Week 8
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Apolipoprotein A-1 at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
Time frame: Baseline, Week 8
The study was conducted at 16 sites in 10 countries. Overall 63 participants were screened between 15 September 2016 and 13 June 2018, of whom 21 participants were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 6 | 4 | 6 | 6 | 5 | 6 | 5 |
| Treated | 4 | 6 | 4 | 6 | 6 | 5 | 6 | 5 |
| Completed | 4 | 6 | 4 | 6 | 6 | 5 | 6 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 6 | 4 | 6 | 6 | 5 | 6 | 5 |
| Treated | 3 | 6 | 4 | 6 | 6 | 5 | 5 | 4 |
| Completed | 3 | 3 | 4 | 6 | 6 | 5 | 5 | 4 |
| Not completed | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Included but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Other than specified | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Percent change in calculated LDL-C was defined as 100\*(calculated LDL-C value at Week 8 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline. All available baseline and post-baseline calculated LDL-C value during the OLDFI efficacy treatment period \& within one of the analysis windows up to Week 8 were used in the model. OLDFI efficacy treatment period was defined as the period from first investigational medicinal product (IMP) injection to last OLDFI IMP injection + 21 days(for Cohorts 1 \& 2) or +35 days (for Cohorts 3 \& 4). Adjusted Least-squares (LS) mean \& standard error (SE) at Week 8 were obtained from mixed-effect model with repeated measures (MMRM) analysis, with fixed categorical effects of alirocumab dose/dose regimen (30 mg Q2W \[\<50 kg\], 40 mg Q2W \[\<50 kg\], 50 mg Q2W \[\>=50 kg\], 75 mg Q2W \[\>=50 kg\], 75 mg Q4W \[\<50 kg\],150 mg Q4W \[\>=50 kg\], 150 mg Q4W \[\<50 kg\] and 300 mg Q4W (\[\>=50 kg\] dose), time point \& dose/dose regimen-by-time point interaction.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8 | -41.1 ± 12.6 | -7.9 ± 10.3 | -40.6 ± 13.2 | -49.8 ± 10.6 | -17.5 ± 10.3 | 4.0 ± 11.2 | -31.9 ± 10.3 | -59.8 ± 11.2 |
Absolute change in LDL-C was calculated by subtracting baseline value from Week 8 value. Adjusted LS means and SE were obtained using MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.
| milligram per deciliter (mg/dL) | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8 | -83.7 ± 19.5 | -27.6 ± 15.9 | -55.5 ± 20.8 | -88.3 ± 16.5 | -32.4 ± 15.9 | 0.1 ± 17.4 | -55.9 ± 15.9 | -104.3 ± 17.4 |
Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
| percentage of participants | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8 | 100.0 | 33.3 | 97.6 | 83.0 | 33.3 | 20.0 | 66.7 | 80.0 |
Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
| percentage of participants | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8 | 0.0 | 0.0 | 93.4 | 65.7 | 16.7 | 20.0 | 66.7 | 80.0 |
Adjusted LS means and standard error at Week 12 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction.
| percent change | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4 | -29.7 ± 6.9 | -49.2 ± 7.5 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline value and post-baseline values in at least one of the analysis windows used in the model.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8 | -38.4 ± 12.8 | -9.7 ± 9.1 | -36.4 ± 12.8 | -40.1 ± 9.9 | -12.6 ± 9.1 | -0.9 ± 9.9 | -27.2 ± 9.1 | -51.4 ± 9.9 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baselines value and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8 | -39.6 ± 11.9 | -7.1 ± 9.7 | -39.7 ± 12.5 | -43.9 ± 10.0 | -14.4 ± 9.7 | 3.2 ± 10.7 | -31.5 ± 9.7 | -54.6 ± 10.7 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8 | -29.0 ± 9.7 | -4.1 ± 7.9 | -28.6 ± 10.1 | -34.2 ± 8.1 | -10.7 ± 7.9 | 5.2 ± 8.6 | -24.0 ± 7.9 | -41.8 ± 8.6 |
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively (with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 8 | 4.5 ± 21.1 | -26.9 ± 11.6 | 1.5 ± 15.1 | -25.2 ± 14.4 | 2.2 ± 10.5 | -7.7 ± 11.4 | 0.1 ± 10.2 | -7.7 ± 11.1 |
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglyceride at Week 8 | -0.4 ± 19.6 | -4.0 ± 16.0 | -7.4 ± 28.4 | 14.5 ± 19.0 | 19.3 ± 16.0 | -3.1 ± 17.5 | -32.1 ± 16.0 | -7.1 ± 17.5 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8 | 9.7 ± 7.1 | 16.5 ± 5.8 | 14.7 ± 7.7 | 10.6 ± 6.1 | 5.2 ± 5.8 | 13.8 ± 6.4 | 4.5 ± 5.8 | 2.8 ± 6.4 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| percent change | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 at Week 8 | 4.4 ± 7.2 | 14.8 ± 5.1 | 10.7 ± 7.2 | 1.8 ± 5.6 | 8.9 ± 5.1 | 7.4 ± 5.6 | 5.8 ± 5.1 | 7.2 ± 5.6 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| mg/dL | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Apolipoprotein B at Week 8 | -51.7 ± 15.8 | -18.5 ± 11.1 | -35.3 ± 15.8 | -53.4 ± 12.2 | -15.3 ± 11.1 | -5.4 ± 12.2 | -34.2 ± 11.1 | -63.5 ± 12.2 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| mg/dL | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8 | -86.1 ± 20.8 | -28.7 ± 17.0 | -62.7 ± 22.1 | -88.5 ± 17.6 | -29.5 ± 17.0 | -0.6 ± 18.6 | -63.1 ± 17.0 | -106.4 ± 18.6 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| mg/dL | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8 | -80.1 ± 21.4 | -20.8 ± 17.5 | -57.1 ± 22.8 | -84.4 ± 18.1 | -27.2 ± 17.5 | 5.3 ± 19.1 | -60.7 ± 17.5 | -105.1 ± 19.1 |
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
| gram/Liter (g/L) | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Lipoprotein(a) at Week 8 | 0.003 ± 0.022 | -0.021 ± 0.017 | 0.007 ± 0.073 | -0.025 ± 0.020 | 0.023 ± 0.018 | -0.031 ± 0.019 | -0.002 ± 0.017 | -0.120 ± 0.020 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| mg/dL | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in HDL-C at Week 8 | 5.9 ± 3.4 | 7.7 ± 2.8 | 5.5 ± 3.7 | 4.9 ± 2.9 | 2.4 ± 2.8 | 5.9 ± 3.1 | 2.2 ± 2.8 | 1.2 ± 3.1 |
Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables.
| mmol/L | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Fasting Triglyceride at Week 8 | -0.121 ± 0.193 | -0.076 ± 0.157 | 0.168 ± 0.226 | 0.111 ± 0.188 | 0.117 ± 0.157 | -0.045 ± 0.172 | -0.402 ± 0.157 | -0.107 ± 0.172 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| mg/dL | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Apolipoprotein A-1 at Week 8 | 4.0 ± 9.3 | 17.7 ± 6.5 | 11.3 ± 9.3 | -0.4 ± 7.2 | 10.5 ± 6.5 | 8.0 ± 7.2 | 7.5 ± 6.5 | 11.0 ± 7.2 |
Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model.
| ratio (Apo B/Apo A-1) | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg |
|---|---|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8 | -0.363 ± 0.123 | -0.262 ± 0.087 | -0.370 ± 0.123 | -0.402 ± 0.096 | -0.190 ± 0.087 | -0.086 ± 0.096 | -0.282 ± 0.087 | -0.473 ± 0.096 |
Collected over All Adverse Events (AEs) were collected from the time of first dose of IMP up to the end of study (Week 152) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Alirocumab 40 Q2W Post-switch | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Alirocumab 75 Q2W Post-switch | 0/18 (0%) | 0/18 (0%) | 9/18 (50%) |
| Event | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg | Alirocumab 40 Q2W Post-switch | Alirocumab 75 Q2W Post-switch |
|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/4 | 2/6 | 0/4 | 0/6 | 1/6 | 0/5 | 1/6 | 1/5 | 0/10 | 0/18 |
| NasopharyngitisInfections and infestations | 1/4 | 2/6 | 0/4 | 1/6 | 0/6 | 1/5 | 0/6 | 0/5 | 1/10 | 2/18 |
| Gastroenteritis ViralInfections and infestations | 1/4 | 0/6 | 0/4 | 0/6 | 1/6 | 0/5 | 0/6 | 0/5 | 3/10 | 1/18 |
| Influenza Like IllnessGeneral disorders | 1/4 | 1/6 | 0/4 | 0/6 | 0/6 | 0/5 | 0/6 | 1/5 | 1/10 | 0/18 |
| Ear InfectionInfections and infestations | 1/4 | 0/6 | 0/4 | 1/6 | 1/6 | 0/5 | 0/6 | 0/5 | 1/10 | 1/18 |
| Infectious MononucleosisInfections and infestations | 1/4 | 0/6 | 0/4 | 0/6 | 0/6 | 0/5 | 0/6 | 0/5 | 0/10 | 0/18 |
| PharyngitisInfections and infestations | 0/4 | 0/6 | 1/4 | 0/6 | 0/6 | 0/5 | 0/6 | 0/5 | 0/10 | 0/18 |
| FallInjury, poisoning and procedural complications | 1/4 | 1/6 | 0/4 | 0/6 | 1/6 | 0/5 | 0/6 | 0/5 | 0/10 | 0/18 |
| Ligament SprainInjury, poisoning and procedural complications | 1/4 | 0/6 | 0/4 | 1/6 | 0/6 | 0/5 | 0/6 | 0/5 | 0/10 | 2/18 |
| Traumatic HaematomaInjury, poisoning and procedural complications | 1/4 | 0/6 | 0/4 | 0/6 | 0/6 | 0/5 | 0/6 | 0/5 | 0/10 | 0/18 |
Analysis was performed on safety population that included population who did actually received at least one dose or part of a dose of the open-label investigational medicinal product (IMP). Participants were analyzed according to the dose of alirocumab actually received.
| Age, Continuous(years) | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 11.0 ± 2.0 | 13.8 ± 2.7 | 11.3 ± 2.2 | 14.3 ± 2.3 | 9.8 ± 1.9 | 13.8 ± 1.6 | 11.3 ± 2.2 | 13.6 ± 2.1 | 12.4 ± 2.6 |
| Sex: Female, Male(Participants) | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 4 | 2 | 2 | 3 | 3 | 1 | 2 | 19 |
| Male | 2 | 2 | 2 | 4 | 3 | 2 | 5 | 3 | 23 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Black or African American/White | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| White | 4 | 6 | 4 | 6 | 5 | 5 | 6 | 3 | 39 |
| Low Density Lipoprotein Cholesterol (LDL-C)(millimoles per litre (mmol/L)) | Cohort 1 - Alirocumab 30 mg Q2W: <50 kg | Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg | Cohort 2 - Alirocumab 40 mg Q2W: <50 kg | Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg | Cohort 3 - Alirocumab 75 mg Q4W: <50 kg | Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg | Cohort 4 - Alirocumab 150 mg Q4W: <50 kg | Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 5.169 ± 0.736 | 4.339 ± 1.200 | 3.596 ± 0.630 | 4.510 ± 1.052 | 4.337 ± 1.147 | 4.642 ± 1.272 | 5.100 ± 1.136 | 4.641 ± 0.926 | 4.6 ± 1.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Sep 2018, 23 months.
Results were first posted in Sep 2019, 11 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 23 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alirocumab · Statins · Ezetimibe · Cholestyramine Resin · Fenofibrate · Omega-3 fatty acid · Niacin